By integrative practitioner staff
Researchers have developed a fluorescent nanosensor that rapidly detects indole-3propionic acid (IPA), a gut microbiome-derived metabolite increasingly recognized as a marker of intestinal inflammation. This technology could provide doctors with a faster and more convenient way to monitor inflammatory bowel disease (IBD) and evaluate responses to nutritional and therapeutic interventions, according to findings published in Advanced healthcare materials (DOI: https://doi.org/10.1002/adhm.202503434).
IPA has emerged as a potential biomarker of gut health. Blood levels are significantly lower in patients with active ulcerative colitis (UC) and Crohn’s disease, but measurement of IPA currently relies on liquid chromatography-mass spectrometry (LC-MS), an expensive specialized technique that limits routine clinical use.
In this study, researchers developed a dual-mode fluorescent nanosensor that rapidly distinguishes blood samples from healthy individuals and patients with UC or active Crohn’s disease based on differences in IPA levels. Rather than replacing LC-MS, the researchers envision the nanosensor serving as a complementary diagnostic tool that could provide an early indicator of gut microbiome disruption and inflammation before symptoms worsen.
IPA levels are strongly influenced by diet. According to the researchers, dietary patterns rich in fiber and polyphenols, such as the Mediterranean diet, increase IPA levels, while Western dietary patterns and high intake of refined carbohydrates reduce them. Low levels of IPA have also been linked to an increased risk of type 2 diabetes and non-alcoholic fatty liver disease, suggesting that the sensor could have applications beyond inflammatory bowel disease.
Researchers believe this technology could ultimately help doctors monitor response to treatment, evaluate personalized nutrition strategies, and objectively evaluate the effects of probiotics, prebiotics, or medical diets in near real-time. They plan to expand the platform into a multiplex sensor capable of detecting multiple gut metabolites simultaneously, providing a more comprehensive picture of gut health. The newly awarded Innovation to Startup grant will support the commercialization of technology and integration of machine learning algorithms designed to improve diagnostic accuracy and create clinically actionable gut health profiles.
To read the full article by Deborah Borwitz, visit Diagnostic World News.
